| pubmed-article:21239717 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21239717 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:21239717 | lifeskim:mentions | umls-concept:C1332717 | lld:lifeskim |
| pubmed-article:21239717 | lifeskim:mentions | umls-concept:C1706438 | lld:lifeskim |
| pubmed-article:21239717 | lifeskim:mentions | umls-concept:C0004561 | lld:lifeskim |
| pubmed-article:21239717 | lifeskim:mentions | umls-concept:C0039194 | lld:lifeskim |
| pubmed-article:21239717 | lifeskim:mentions | umls-concept:C0003320 | lld:lifeskim |
| pubmed-article:21239717 | lifeskim:mentions | umls-concept:C0085358 | lld:lifeskim |
| pubmed-article:21239717 | lifeskim:mentions | umls-concept:C1749467 | lld:lifeskim |
| pubmed-article:21239717 | lifeskim:mentions | umls-concept:C1413244 | lld:lifeskim |
| pubmed-article:21239717 | lifeskim:mentions | umls-concept:C2698600 | lld:lifeskim |
| pubmed-article:21239717 | lifeskim:mentions | umls-concept:C0056912 | lld:lifeskim |
| pubmed-article:21239717 | lifeskim:mentions | umls-concept:C0449450 | lld:lifeskim |
| pubmed-article:21239717 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:21239717 | pubmed:dateCreated | 2011-2-3 | lld:pubmed |
| pubmed-article:21239717 | pubmed:abstractText | Naive B lymphocytes are generally thought to be poor APCs, and there is limited knowledge of their role in activation of CD8(+) T cells. In this article, we demonstrate that class I MHC Ag presentation by human naive B cells is enhanced by TLR9 agonists. Purified naive B cells were cultured with or without a TLR9 agonist (CpG oligodeoxynucleotide [ODN] 2006) for 2 d and then assessed for phenotype, endocytic activity, and their ability to induce CD8(+) T cell responses to soluble Ags. CpG ODN enhanced expression of class I MHC and the costimulatory molecule CD86 and increased endocytic activity as determined by uptake of dextran beads. Pretreatment of naive B cells with CpG ODN also enabled presentation of tetanus toxoid to CD8(+) T cells, resulting in CD8(+) T cell cytokine production and granzyme B secretion and proliferation. Likewise, CpG-activated naive B cells showed enhanced ability to cross-present CMV Ag to autologous CD8(+) T cells, resulting in proliferation of CMV-specific CD8(+) T cells. Although resting naive B cells are poor APCs, they can be activated by TLR9 agonists to serve as potent APCs for class I MHC-restricted T cell responses. This novel activity of naive B cells could be exploited for vaccine design. | lld:pubmed |
| pubmed-article:21239717 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21239717 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21239717 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21239717 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21239717 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21239717 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21239717 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21239717 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21239717 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21239717 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21239717 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21239717 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21239717 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:21239717 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21239717 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21239717 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21239717 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21239717 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21239717 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21239717 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21239717 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21239717 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21239717 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:21239717 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:21239717 | pubmed:issn | 1550-6606 | lld:pubmed |
| pubmed-article:21239717 | pubmed:author | pubmed-author:WeiJiangJ | lld:pubmed |
| pubmed-article:21239717 | pubmed:author | pubmed-author:LedermanMicha... | lld:pubmed |
| pubmed-article:21239717 | pubmed:author | pubmed-author:SiegScott FSF | lld:pubmed |
| pubmed-article:21239717 | pubmed:author | pubmed-author:HardingCliffo... | lld:pubmed |
| pubmed-article:21239717 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:21239717 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:21239717 | pubmed:volume | 186 | lld:pubmed |
| pubmed-article:21239717 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21239717 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21239717 | pubmed:pagination | 2080-6 | lld:pubmed |
| pubmed-article:21239717 | pubmed:dateRevised | 2011-10-6 | lld:pubmed |
| pubmed-article:21239717 | pubmed:meshHeading | pubmed-meshheading:21239717... | lld:pubmed |
| pubmed-article:21239717 | pubmed:meshHeading | pubmed-meshheading:21239717... | lld:pubmed |
| pubmed-article:21239717 | pubmed:meshHeading | pubmed-meshheading:21239717... | lld:pubmed |
| pubmed-article:21239717 | pubmed:meshHeading | pubmed-meshheading:21239717... | lld:pubmed |
| pubmed-article:21239717 | pubmed:meshHeading | pubmed-meshheading:21239717... | lld:pubmed |
| pubmed-article:21239717 | pubmed:meshHeading | pubmed-meshheading:21239717... | lld:pubmed |
| pubmed-article:21239717 | pubmed:meshHeading | pubmed-meshheading:21239717... | lld:pubmed |
| pubmed-article:21239717 | pubmed:meshHeading | pubmed-meshheading:21239717... | lld:pubmed |
| pubmed-article:21239717 | pubmed:meshHeading | pubmed-meshheading:21239717... | lld:pubmed |
| pubmed-article:21239717 | pubmed:meshHeading | pubmed-meshheading:21239717... | lld:pubmed |
| pubmed-article:21239717 | pubmed:meshHeading | pubmed-meshheading:21239717... | lld:pubmed |
| pubmed-article:21239717 | pubmed:meshHeading | pubmed-meshheading:21239717... | lld:pubmed |
| pubmed-article:21239717 | pubmed:meshHeading | pubmed-meshheading:21239717... | lld:pubmed |
| pubmed-article:21239717 | pubmed:meshHeading | pubmed-meshheading:21239717... | lld:pubmed |
| pubmed-article:21239717 | pubmed:meshHeading | pubmed-meshheading:21239717... | lld:pubmed |
| pubmed-article:21239717 | pubmed:meshHeading | pubmed-meshheading:21239717... | lld:pubmed |
| pubmed-article:21239717 | pubmed:meshHeading | pubmed-meshheading:21239717... | lld:pubmed |
| pubmed-article:21239717 | pubmed:meshHeading | pubmed-meshheading:21239717... | lld:pubmed |
| pubmed-article:21239717 | pubmed:meshHeading | pubmed-meshheading:21239717... | lld:pubmed |
| pubmed-article:21239717 | pubmed:meshHeading | pubmed-meshheading:21239717... | lld:pubmed |
| pubmed-article:21239717 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:21239717 | pubmed:articleTitle | Presentation of soluble antigens to CD8+ T cells by CpG oligodeoxynucleotide-primed human naive B cells. | lld:pubmed |
| pubmed-article:21239717 | pubmed:affiliation | Division of Infectious Diseases and HIV Medicine, Case Western Reserve University, University Hospitals/Case Medical Center, Cleveland, OH 44106, USA. wei.jiang@case.edu | lld:pubmed |
| pubmed-article:21239717 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:21239717 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |
